Celin Sabu

My first breakthrough into the pharmaceutical industry was in Canada, where I joined AstraZeneca and was given one of a few of their most pivotal trials, which led to approvals into various indications like ovarian cancer and lung cancer. I worked with AstraZeneca, providing my leadership and expertise and working with a cross-functional team for around 4 years. After that, I moved on to Roche Genentech in Canada itself, where I was leading their programs into adaptive immune oncology studies, which was a step further from what I did in AstraZeneca. I worked with them for around 3 years, and then we had to move to the United States in 2022 because I wanted to work in the South. I started my first career here with Bristol-Myers Squibb, working on one of their pivotal programs on cell therapy. I was fortunate enough to have the experience of going through the whole FDA inspection and getting the product approved, accelerated approval. In between all these, I also had a feeling that I should be giving back to the society, so I was teaching and was a professor in New York University in Canada and also in one of the leading universities in Mumbai, where I taught about clinical research to graduates. I have done a few publications, really four or five of them, and I am a current volunteer for Clinical Research Association of Canada, where I do multiple webinars. I was recently invited even by Hyegia Group to provide a webinar on cell therapy, upcoming challenges and decisions. The whole time, the motivation was seeing cancer patients suffering through this dreadful disease and not having an option to make a decision for their own life. That was the trigger point to work in this field and the whole passion that drives me to come to work every day.